Login to Your Account

Other shoe drops for Newlink after Genentech passes on GDC-0919

By Marie Powers
News Editor

Thursday, June 8, 2017

Shares of Newlink Genetics Corp. were dented 12.4 percent on Monday after the company reported a failed phase II experiment with lead program indoximod, in combination with taxane chemotherapy, for patients with metastatic breast cancer, based on top-line data.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription